JPRN-jRCT2080223661已完成3 期
Phase III study of HFT-290 in patients with cancer
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 209
研究概览
简要总结
HFT-290 was administered to 208 of 209 enrolled patients. In the FAS, the response rate (95% confidence interval) was 87.0 (81.7-91.3)%. The lower limit of the 95% confidence interval of the response rate was higher than the threshold response rate, indicating the efficacy of HFT-290. Following dose escalation to 4 mg, respiratory depression occurred in one patient; however, this was considered a mild adverse event.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients confirmed to have various types of cancer who were informed about their disease.
排除标准
- •- Patients with abnormalities at the planned application site.
- •- Patients with serious cardiac, hepatic, or renal dysfunction, serious respiratory disorders, serious respiratory depression.
研究者
相似试验
未知
3 期
A phase III clinical study of HFT-290.Cancer painJPRN-jRCT2080223308Hisamitsu Pharmaceutical Co.,Inc.
已完成
3 期
Phase III study of HFT-290Cancer painJPRN-jRCT2080223853Hisamitsu Pharmaceutical Co., Inc.11
已完成
3 期
Phase III study of HP-3150Cancer painJPRN-jRCT2080223595Hisamitsu Pharmaceutical Co., Inc.341
未知
3 期
Phase III clinical study in patients with chronic paiChronic painJPRN-jRCT2080221563Hisamitsu Pharmaceutical Co., Inc.
尚未招募
2 期
A phase II study of HFNC in advanced cancer patients with dyspnea and poor PSadvanced cancerJPRN-UMIN000035738Wakayama Medical University24